$CMPS
Compass Pathways PLC Stock $cmps

$cmps Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000162828024021351 Filed on May 08, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$14.25M	$11.23M	$9.192M
YoY Change	48.67%	6.29%	-10.1%
% of Gross Profit
Research & Development	$29.07M	$24.90M	$27.14M
YoY Change	46.68%	30.82%	37.11%
% of Gross Profit
Depreciation & Amortization	$63.00K	$61.00K	-$102.0K
YoY Change	-42.73%	27.08%	-206.25%
% of Gross Profit
Operating Expenses	$43.32M	$38.57M	$36.33M
YoY Change	47.33%	21.34%	21.03%
Operating Profit	-$43.32M	-$38.57M
YoY Change	32.63%	21.34%
Interest Expense	$1.521M	$1.098M	$498.0K
YoY Change	10.54%	-59.11%	-113.97%
% of Operating Profit
Other Income/Expense, Net	$5.397M	$3.608M	$5.769M
YoY Change	71.5%	-53.2%	17.18%
Pretax Income	-$37.93M	-$34.97M	-$32.14M
YoY Change	34.77%	45.22%	4.23%
Income Tax	$176.0K	$222.0K	$394.0K
% Of Pretax Income
Net Earnings	-$38.10M	-$35.19M	-$32.53M
YoY Change	34.47%	45.35%	5.19%
Net Earnings / Revenue
Basic Earnings Per Share	-$560.00	-$0.55
Diluted Earnings Per Share	-$560.00	-$0.55	-$0.52
COMMON SHARES
Basic Shares Outstanding	68.38M shares	64.23M shares	61.90M shares
Diluted Shares Outstanding	68.37M shares	64.22M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$228.6M	$262.9M	$220.2M
YoY Change	54.23%	124.49%	53.76%
Cash & Equivalents	$228.6M	$262.9M	$220.2M
Short-Term Investments
Other Short-Term Assets	$2.699M	$1.719M	$1.895M
YoY Change	-87.92%	15.37%	100.53%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$265.1M	$295.5M	$261.3M
YoY Change	36.93%	76.08%	36.34%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.179M	$359.0K	$423.0K
YoY Change	-39.63%	-41.34%	-31.44%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$469.0K	$469.0K
YoY Change		0.0%	0.0%
Other Assets	$6.239M	$6.097M	$7.049M
YoY Change	-40.57%	2775.94%	2055.66%
Total Long-Term Assets	$13.44M	$13.48M	$14.69M
YoY Change	-17.21%	145.77%	160.34%
TOTAL ASSETS
Total Short-Term Assets	$265.1M	$295.5M	$261.3M
Total Long-Term Assets	$13.44M	$13.48M	$14.69M
Total Assets	$278.5M	$309.0M	$276.0M
YoY Change	32.74%	78.29%	39.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.195M	$9.342M	$5.892M
YoY Change	313.47%	141.08%	23.76%
Accrued Expenses	$13.83M	$8.513M	$12.69M
YoY Change	37.05%	26.93%	24.64%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$22.03M	$19.40M	$19.60M
YoY Change	72.42%	72.4%	25.7%
LONG-TERM LIABILITIES
Long-Term Debt	$29.43M	$29.09M	$28.76M
YoY Change	4.66%
Other Long-Term Liabilities	$799.0K	$1.339M	$1.882M
YoY Change	-68.53%	225.0%	350.24%
Total Long-Term Liabilities	$30.23M	$30.43M	$30.64M
YoY Change	-1.4%	7285.68%	7229.9%
TOTAL LIABILITIES
Total Short-Term Liabilities	$22.03M	$19.40M	$19.60M
Total Long-Term Liabilities	$30.23M	$30.43M	$30.64M
Total Liabilities	$52.26M	$49.83M	$50.24M
YoY Change	20.31%	327.15%	213.74%
SHAREHOLDERS EQUITY
Retained Earnings	-$452.9M	-$414.8M	-$379.6M
YoY Change	44.37%	45.36%	45.36%
Common Stock	$699.0K	$699.0K	$635.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$226.3M	$259.2M	$225.7M
YoY Change
Total Liabilities & Shareholders Equity	$278.5M	$309.0M	$276.0M
YoY Change	32.74%	78.29%	39.89%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q4
OPERATING ACTIVITIES
Net Income	-$38.10M	-$35.19M	-$32.53M
YoY Change	34.47%	45.35%	5.19%
Depreciation, Depletion And Amortization	$63.00K	$61.00K	-$102.0K
YoY Change	-42.73%	27.08%	-206.25%
Cash From Operating Activities	-$34.42M	-$20.83M	-$27.78M
YoY Change	38.7%	-24.87%	-38.67%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	-$4.000K
YoY Change	-100.0%	-100.0%	-103.74%
Acquisitions
YoY Change
Other Investing Activities	$0.00		$2.000K
YoY Change	-100.0%
Cash From Investing Activities	$0.00	$0.00	-$4.000K
YoY Change	-100.0%	-100.0%	-96.26%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	210.0K	$63.51M	41.00K
YoY Change	-99.62%	5786.19%	-93.58%
NET CHANGE
Cash From Operating Activities	-34.42M	-$20.83M	-27.78M
Cash From Investing Activities	0.000	$0.00	-4.000K
Cash From Financing Activities	210.0K	$63.51M	41.00K
Net Change In Cash	-34.21M	$42.64M	-27.74M
YoY Change	-209.99%	-263.95%	-38.04%
FREE CASH FLOW
Cash From Operating Activities	-$34.42M	-$20.83M	-$27.78M
Capital Expenditures	$0.00	$0.00	-$4.000K
Free Cash Flow	-$34.42M	-$20.83M	-$27.78M
YoY Change	38.6%	-24.95%	-38.83%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Prepaid Taxes PrepaidTaxes	1123000	usd
CY2023Q4	us-gaap	Prepaid Taxes PrepaidTaxes	1123000	usd
CY2024Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	31115000	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	39535000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	295515000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	261296000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3722000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4306000	usd
CY2024Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	3659000	usd
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	3336000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6097000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7049000	usd
CY2024Q1	us-gaap	Assets Assets	308993000	usd
CY2023Q4	us-gaap	Assets Assets	275987000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	9342000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-34965000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-35187000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5892000	usd
CY2024Q1	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	7680000	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	11301000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2380000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2411000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	19402000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19604000	usd
CY2024Q1	us-gaap	Long Term Debt LongTermDebt	29090000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	28757000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1339000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1882000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	49831000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	50243000	usd
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.008
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.008
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	68342534	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	68342534	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	61943471	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	61943471	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	61943471	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	699000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	635000	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	690222000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	621645000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-16962000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-16926000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-414797000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-379610000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	259162000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	225744000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	308993000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	275987000	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	38573000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	31788000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-38573000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-31788000	usd
CY2024Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	2388000	usd
CY2023Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	709000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	1098000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	0	usd
CY2024Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-783000	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	2685000	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3608000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7710000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-24078000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	222000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	130000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-35187000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-24208000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.55
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.55
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.57
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.57
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	64222178	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	64222178	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42725863	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42725863	shares
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-35187000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-24208000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-36000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-578000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-35223000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-24786000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	181280000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1188000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2023Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	109000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4071000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-578000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-24208000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	161644000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	225744000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	220000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	26219000	usd
CY2024Q1	cmps	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	37258000	usd
CY2024Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	185000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5129000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-36000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-35187000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	259162000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-35187000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-24208000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	61000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	48000	usd
CY2024Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	333000	usd
CY2023Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	usd
CY2024Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-230000	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	2107000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	5129000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4071000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	555000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	539000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-8136000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1484000	usd
CY2024Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	322000	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-129000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-837000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	44000	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-545000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-478000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3517000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-973000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-3572000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-3216000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20828000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-27723000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	29000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-29000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	26219000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1188000	usd
CY2024Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	37258000	usd
CY2023Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
CY2024Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	185000	usd
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	109000	usd
CY2024Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	220000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	63512000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1079000	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-45000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	666000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	42639000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-26007000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	220638000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	143381000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	263277000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	117374000	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	765000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	262888000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	117103000	usd
CY2024Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	389000	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	271000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	263277000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	117374000	usd
CY2021Q4	cmps	Number Of Ordinary Shares Conversion Ratio NumberOfOrdinarySharesConversionRatio	1
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-35200000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-24200000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-414800000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	262900000	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, research and development expenses and the research and development tax credit. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.</span></div>
CY2024Q1	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	500000	usd
CY2024Q1	us-gaap	Equity Securities Without Readily Determinable Fair Value Impairment Loss Cumulative Amount EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount	0	usd
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject the Company to credit risk consist primarily of cash and cash equivalents. The Company places cash and cash equivalents in diversified and established financial institutions. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. The Company has cash and cash equivalents in excess of the FDIC insured limit. The Company has no significant off-balance-sheet risk or concentration of credit risk, such as foreign exchange contracts, options contracts, or other foreign hedging arrangements</span></div>
CY2024Q1	cmps	Number Of Geographic Regions NumberOfGeographicRegions	2	region
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2024Q1	cmps	Research And Development Expenditures Tax Credit Connected Parties Maximum Percentage Of Total Claim ResearchAndDevelopmentExpendituresTaxCreditConnectedPartiesMaximumPercentageOfTotalClaim	0.15
CY2023Q3	cmps	Number Of Ordinary Shares Conversion Ratio NumberOfOrdinarySharesConversionRatio	1
CY2024Q1	cmps	Research And Development Tax Credit Current ResearchAndDevelopmentTaxCreditCurrent	16155000	usd
CY2023Q4	cmps	Research And Development Tax Credit Current ResearchAndDevelopmentTaxCreditCurrent	27877000	usd
CY2024Q1	cmps	Prepaid Expense Research And Development Current PrepaidExpenseResearchAndDevelopmentCurrent	10538000	usd
CY2023Q4	cmps	Prepaid Expense Research And Development Current PrepaidExpenseResearchAndDevelopmentCurrent	6826000	usd
CY2024Q1	us-gaap	Prepaid Insurance PrepaidInsurance	1374000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1885000	usd
CY2024Q1	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	1329000	usd
CY2023Q4	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	1052000	usd
CY2024Q1	us-gaap	Other Assets Current OtherAssetsCurrent	1719000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1895000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	31115000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	39535000	usd
CY2024Q1	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	14600000	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	11301000	usd
CY2024Q1	us-gaap	Deferred Finance Costs Gross DeferredFinanceCostsGross	3300000	usd
CY2024Q1	cmps	Options Number Of Shares Available For Purchase Percent Of Principal Amount Of Term Loan Advances OptionsNumberOfSharesAvailableForPurchasePercentOfPrincipalAmountOfTermLoanAdvances	0.025
CY2024Q1	cmps	Prepaid Research And Development Noncurrent PrepaidResearchAndDevelopmentNoncurrent	5267000	usd
CY2023Q4	cmps	Prepaid Research And Development Noncurrent PrepaidResearchAndDevelopmentNoncurrent	5955000	usd
CY2024Q1	us-gaap	Other Investments OtherInvestments	469000	usd
CY2023Q4	us-gaap	Other Investments OtherInvestments	469000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	359000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	423000	usd
CY2024Q1	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	2000	usd
CY2023Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	202000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6097000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7049000	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3119000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7069000	usd
CY2024Q1	cmps	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	1487000	usd
CY2023Q4	cmps	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	2117000	usd
CY2024Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1247000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1077000	usd
CY2024Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	544000	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	0	usd
CY2024Q1	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	280000	usd
CY2023Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	13000	usd
CY2024Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1003000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1025000	usd
CY2024Q1	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	7680000	usd
CY2024Q1	cmps	Options Exercisable Number OptionsExercisableNumber	94222	shares
CY2024Q1	cmps	Options Exercisable Fair Value OptionsExercisableFairValue	700000	usd
CY2024Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	30000000	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	30000000	usd
CY2024Q1	cmps	Long Term Debt End Of Term Charge LongTermDebtEndOfTermCharge	1425000	usd
CY2023Q4	cmps	Long Term Debt End Of Term Charge LongTermDebtEndOfTermCharge	1425000	usd
CY2024Q1	cmps	Long Term Debt Including End Of Term Charge LongTermDebtIncludingEndOfTermCharge	31425000	usd
CY2023Q4	cmps	Long Term Debt Including End Of Term Charge LongTermDebtIncludingEndOfTermCharge	31425000	usd
CY2024Q1	cmps	Debt Instrument Paid In Kind Interest Payable DebtInstrumentPaidInKindInterestPayable	324000	usd
CY2023Q4	cmps	Debt Instrument Paid In Kind Interest Payable DebtInstrumentPaidInKindInterestPayable	216000	usd
CY2024Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	2659000	usd
CY2023Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	2884000	usd
CY2024Q1	us-gaap	Long Term Debt LongTermDebt	29090000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	28757000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	0	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	6572000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	14166000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	10687000	usd
CY2024Q1	cmps	Long Term Debt Including End Of Term Charge LongTermDebtIncludingEndOfTermCharge	31425000	usd
CY2024Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	1100000	usd
CY2023Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	0	usd
CY2024Q1	cmps	Cash Dividend Declared Or Paid During Period CashDividendDeclaredOrPaidDuringPeriod	0	usd
CY2021Q4	cmps	Number Of Ordinary Shares Conversion Ratio NumberOfOrdinarySharesConversionRatio	1
CY2023Q3	cmps	Number Of Ordinary Shares Conversion Ratio NumberOfOrdinarySharesConversionRatio	1
CY2024Q1	cmps	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice	10.89
CY2023Q1	cmps	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice	10.85
CY2023Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	87000	usd
CY2024Q1	us-gaap	Lease Cost LeaseCost	638000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	660000	usd
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	628000	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5129000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4071000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6969328	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.14
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M23D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	14070000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2073529	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	10.38
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	86510	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.48
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	768841	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	17.16
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8187506	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.17
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y11M19D
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	15288000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3780781	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	12.77
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y8M15D
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	11553000	usd
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	4406725	shares
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	11.66
CY2024Q1	cmps	Share Based Compensation Arrangement By Share Based Payment Award Nonvested Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm	P9Y14D
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Nonvested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested	3735000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	700000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.03
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.27
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	39000000.0	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	42300000	usd
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y5M12D
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y18D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8757
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8712
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0392
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0347
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-35187000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-24208000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-35187000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-35187000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-24208000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-24208000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	64222178	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	64222178	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42725863	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42725863	shares
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.55
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.55
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.57
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.57
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	21254085	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7442071	shares
CY2023Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P3Y
CY2023Q4	cmps	Lessee Operating Lease Annual Increase In Lease Payments LesseeOperatingLeaseAnnualIncreaseInLeasePayments	0.035
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	700000	usd
CY2023Q4	cmps	Lessee Operating Lease Noncancelable Term LesseeOperatingLeaseNoncancelableTerm	P2Y
CY2023Q4	cmps	Lessee Operating Lease Termination Period Minimum Lease Term LesseeOperatingLeaseTerminationPeriodMinimumLeaseTerm	P2Y
CY2023Q4	cmps	Lessee Operating Lease Termination Fee Period LesseeOperatingLeaseTerminationFeePeriod	P3M
CY2024Q1	cmps	Lease Deposit Payments LeaseDepositPayments	0	gbp
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	638000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	573000	usd
CY2024Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	562000	usd
CY2024Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	102000	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y8M12D
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y7M6D
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0850
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0601
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1861000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1809000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	227000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	96000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3993000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	274000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	3719000	usd
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001628280-24-021351-index-headers.html	Edgar Link	pending
0001628280-24-021351-index.html	Edgar Link	pending
0001628280-24-021351.txt	Edgar Link	pending
0001628280-24-021351-xbrl.zip	Edgar Link	pending
cmps-20240331.htm	Edgar Link	pending
cmps-20240331.xsd	Edgar Link	pending
cmps-q1x24xex311ceo302cert.htm	Edgar Link	pending
cmps-q1x24xex312cfo302cert.htm	Edgar Link	pending
cmps-q1x24xex321ceoxcfosec.htm	Edgar Link	pending
exhibit101mattemployment.htm	Edgar Link	pending
exhibit101mattemployment001.jpg	Edgar Link	pending
exhibit101mattemployment002.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
cmps-20240331_def.xml	Edgar Link	unprocessable
cmps-20240331_lab.xml	Edgar Link	unprocessable
cmps-20240331_htm.xml	Edgar Link	completed
cmps-20240331_pre.xml	Edgar Link	unprocessable
0001628280-24-021351-index-headers.html	Edgar Link	pending
0001628280-24-021351-index.html	Edgar Link	pending
0001628280-24-021351.txt	Edgar Link	pending
0001628280-24-021351-xbrl.zip	Edgar Link	pending
cmps-20240331.htm	Edgar Link	pending
cmps-20240331.xsd	Edgar Link	pending
cmps-20240331_cal.xml	Edgar Link	unprocessable
cmps-20240331_def.xml	Edgar Link	unprocessable
cmps-20240331_lab.xml	Edgar Link	unprocessable
cmps-20240331_pre.xml	Edgar Link	unprocessable
cmps-20240331_htm.xml	Edgar Link	completed
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ukemploymentagreementkab.htm	Edgar Link	pending
ukemploymentagreementkab001.jpg	Edgar Link	pending
ukemploymentagreementkab002.jpg	Edgar Link	pending
ukemploymentagreementkab003.jpg	Edgar Link	pending
ukemploymentagreementkab004.jpg	Edgar Link	pending
ukemploymentagreementkab005.jpg	Edgar Link	pending
ukemploymentagreementkab006.jpg	Edgar Link	pending
ukemploymentagreementkab007.jpg	Edgar Link	pending
ukemploymentagreementkab008.jpg	Edgar Link	pending
ukemploymentagreementkab009.jpg	Edgar Link	pending
ukemploymentagreementkab010.jpg	Edgar Link	pending
ukemploymentagreementkab011.jpg	Edgar Link	pending
ukemploymentagreementkab012.jpg	Edgar Link	pending
ukemploymentagreementkab013.jpg	Edgar Link	pending
ukemploymentagreementkab014.jpg	Edgar Link	pending
ukemploymentagreementkab015.jpg	Edgar Link	pending
ukemploymentagreementkab016.jpg	Edgar Link	pending
ukemploymentagreementkab017.jpg	Edgar Link	pending
ukemploymentagreementkab018.jpg	Edgar Link	pending
ukemploymentagreementkab019.jpg	Edgar Link	pending
ukemploymentagreementkab020.jpg	Edgar Link	pending
ukemploymentagreementkab021.jpg	Edgar Link	pending
ukemploymentagreementkab022.jpg	Edgar Link	pending
ukemploymentagreementkab023.jpg	Edgar Link	pending
ukemploymentagreementkab024.jpg	Edgar Link	pending
ukemploymentagreementkab025.jpg	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ukemploymentagreementkab.htm	Edgar Link	pending
ukemploymentagreementkab001.jpg	Edgar Link	pending
ukemploymentagreementkab002.jpg	Edgar Link	pending
ukemploymentagreementkab003.jpg	Edgar Link	pending
ukemploymentagreementkab004.jpg	Edgar Link	pending
ukemploymentagreementkab005.jpg	Edgar Link	pending
ukemploymentagreementkab006.jpg	Edgar Link	pending
ukemploymentagreementkab007.jpg	Edgar Link	pending
ukemploymentagreementkab008.jpg	Edgar Link	pending
ukemploymentagreementkab009.jpg	Edgar Link	pending
ukemploymentagreementkab010.jpg	Edgar Link	pending
ukemploymentagreementkab011.jpg	Edgar Link	pending
ukemploymentagreementkab012.jpg	Edgar Link	pending
ukemploymentagreementkab013.jpg	Edgar Link	pending
ukemploymentagreementkab014.jpg	Edgar Link	pending
ukemploymentagreementkab015.jpg	Edgar Link	pending
ukemploymentagreementkab016.jpg	Edgar Link	pending
ukemploymentagreementkab017.jpg	Edgar Link	pending
ukemploymentagreementkab018.jpg	Edgar Link	pending
ukemploymentagreementkab019.jpg	Edgar Link	pending
ukemploymentagreementkab020.jpg	Edgar Link	pending
ukemploymentagreementkab021.jpg	Edgar Link	pending
ukemploymentagreementkab022.jpg	Edgar Link	pending
ukemploymentagreementkab023.jpg	Edgar Link	pending
ukemploymentagreementkab024.jpg	Edgar Link	pending
ukemploymentagreementkab025.jpg	Edgar Link	pending
cmps-q1x24xex311ceo302cert.htm	Edgar Link	pending
cmps-q1x24xex312cfo302cert.htm	Edgar Link	pending
cmps-q1x24xex321ceoxcfosec.htm	Edgar Link	pending
exhibit101mattemployment.htm	Edgar Link	pending
exhibit101mattemployment001.jpg	Edgar Link	pending
exhibit101mattemployment002.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
cmps-20240331_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CMPS
Compass Pathways PLC Stock $cmps

2024 Q2 Form 10-Q Financial Statement

#000162828024021351 Filed on May 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CMPS Compass Pathways PLC Stock $cmps

2024 Q2 Form 10-Q Financial Statement

#000162828024021351 Filed on May 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CMPS
Compass Pathways PLC Stock $cmps